Literature DB >> 11447235

Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo.

K R Kozak1, B C Crews, J L Ray, H H Tai, J D Morrow, L J Marnett.   

Abstract

Prostaglandin glycerol esters (PG-Gs) and prostaglandin ethanolamides (PG-EAs) are generated by the action of cyclooxygenase-2 on the endocannabinoids 2-arachidonylglycerol (2-AG) and arachidonylethanolamide, respectively. These novel eicosanoids may have unique pharmacological properties and/or serve as latent sources of prostaglandins at sites remote from their tissue of origin. Therefore, we investigated the metabolism of PG-Gs and PG-EAs in vitro and in vivo. PGE(2)-G was rapidly hydrolyzed in rat plasma to generate PGE(2) (t(1/2) = 14 s) but was only slowly metabolized in human plasma (t(1/2) > 10 min). An intermediate extent of metabolism of PGE(2)-G was observed in human whole blood (t(1/2) approximately 7 min). The parent arachidonylglycerol, 2-AG, and the more stable regioisomer, 1-AG, also were much more rapidly metabolized in rat plasma compared with human plasma. PGE(2)-EA was not significantly hydrolyzed in plasma, undergoing slow dehydration/isomerization to PGB(2)-EA. Both PGE(2)-G and PGE(2)-EA were stable in canine, bovine, and human cerebrospinal fluid. Human 15-hydroxyprostaglandin dehydrogenase, the enzyme responsible for the initial step in PG inactivation in vivo, oxidized both PGE(2)-G and PGE(2)-EA less efficiently than the free acid. The sterically hindered glyceryl prostaglandin was the poorest substrate examined in the E series. Minimal 15-hydroxyprostaglandin dehydrogenase oxidation of PGF(2 alpha)-G was observed. PGE(2)-G and PGE(2)-EA pharmacokinetics were assessed in rats. PGE(2)-G was not detected in plasma 5 min following an intravenous dose of 2 mg/kg. However, PGE(2)-EA was detectable up to 2 h following an identical dose, displaying a large apparent volume of distribution and a half-life of over 6 min. The results suggest that endocannabinoid-derived PG-like compounds may be sufficiently stable in humans to exert actions systemically. Furthermore, these results suggest that the rat is not an adequate model for investigating the biological activities of 2-arachidonylglycerol or glyceryl prostaglandins in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11447235     DOI: 10.1074/jbc.M105854200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  The endocannabinoid system: a general view and latest additions.

Authors:  Luciano De Petrocellis; Maria Grazia Cascio; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

2.  Biopolymer-based delivery systems for advanced imaging and skeletal tissue-specific therapeutics.

Authors:  Scott C Miller; Dong Wang; Pavla Kopecková; Jindrich Kopecek
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

3.  Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carboxylesterases 1 and 2.

Authors:  Shuqi Xie; Abdolsamad Borazjani; M Jason Hatfield; Carol C Edwards; Philip M Potter; Matthew K Ross
Journal:  Chem Res Toxicol       Date:  2010-12-20       Impact factor: 3.739

4.  13-Methylarachidonic acid is a positive allosteric modulator of endocannabinoid oxygenation by cyclooxygenase.

Authors:  Shalley N Kudalkar; Spyros P Nikas; Philip J Kingsley; Shu Xu; James J Galligan; Carol A Rouzer; Surajit Banerjee; Lipin Ji; Marsha R Eno; Alexandros Makriyannis; Lawrence J Marnett
Journal:  J Biol Chem       Date:  2015-02-02       Impact factor: 5.157

5.  Identification of prostamides, fatty acyl ethanolamines, and their biosynthetic precursors in rabbit cornea.

Authors:  Paula Urquhart; Jenny Wang; David F Woodward; Anna Nicolaou
Journal:  J Lipid Res       Date:  2015-05-31       Impact factor: 5.922

Review 6.  Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation.

Authors:  Daniel J Hermanson; Joyonna C Gamble-George; Lawrence J Marnett; Sachin Patel
Journal:  Trends Pharmacol Sci       Date:  2014-05-18       Impact factor: 14.819

Review 7.  Lipidomic analysis of endocannabinoid metabolism in biological samples.

Authors:  Giuseppe Astarita; Daniele Piomelli
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-01-14       Impact factor: 3.205

Review 8.  Cyclooxygenases: structural and functional insights.

Authors:  Carol A Rouzer; Lawrence J Marnett
Journal:  J Lipid Res       Date:  2008-10-23       Impact factor: 5.922

9.  Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity.

Authors:  S Shu-Jung Hu; H B Bradshaw; J S-C Chen; B Tan; J Michael Walker
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

Review 10.  Dynamic regulation of the endocannabinoid system: implications for analgesia.

Authors:  Devi Rani Sagar; A Gemma Gaw; Bright N Okine; Stephen G Woodhams; Amy Wong; David A Kendall; Victoria Chapman
Journal:  Mol Pain       Date:  2009-10-08       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.